[ad_1]
TThe Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the Abecma brand by its manufacturers, Bristol Myers Squibb and Bluebird Bio.
Multiple myeloma is cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney damage, bone destruction, and impaired immune function.
Unlock this article by subscribing to STAT + and enjoy your first 30 days free!
TO START
What is that?
STAT + is STAT’s premium subscription service for in-depth coverage and analysis in biotechnology, pharmacy, policy and life sciences. Our award-winning team covers the news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and the disruption of healthcare in Silicon Valley and beyond.
What is included?
- Daily reports and analyzes
- The most comprehensive coverage in the industry by a team of powerful journalists
- Subscriber newsletters
- Daily newsletters to keep you informed about the most important news in the sector
- STAT + conversations
- Weekly opportunities to engage with our journalists and leading industry experts in live video chats
- Exclusive industry events
- Premium access to subscriber-only networking events nationwide
- The best reporters in the industry
- The most trusted and connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and high-end tools, like our CRISPR Trackr.
[ad_2]
Source link